InChI=1S/C22H22O10/c1-29-15-5-2-10(6-14(15)24)13-9-30-16-7-11(3-4-12(16)18(13)25)31-22-21(28)20(27)19(26)17(8-23)32-22/h2-7,9,17,19-24,26-28H,8H2,1H3/t17-,19-,20+,21-,22-/m1/s1

Calycosin-7-O-β-d-glucoside(CG) treatment can significantly reduce infarct volume, histological damage and BBB permeability in the in vivo MCAO ischemia–reperfusion rat model; inhibit the expression and activities of MMPs, and secure the expression of cav-1 and tight junction proteins in the microvessels isolated from ischemic rat cortex; scavenge NO, inhibit the activities of MMP-2 and MMP-9, and attenuate cell death in the in vitro cultured brain microvascular endothelial cells under OGD condition; thus CG could protect BBB integrity in experimental cerebral ischemia–reperfusion injury via regulating NO/cav-1/MMPs pathway.[1]
Calycosin-7-O-β-D-glucoside can promote oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells.[2]
Calycosin-7-O-β-d-glucoside attenuates ischemia-reperfusion injuryin vivovia activation of the PI3K/Akt pathway.[3]
Calycosin-7-O-β-D-glucoside has effects on cell apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax.[4]

English website: Calycosin-7-O-beta-D-glucoside
Japanese website: Calycosin-7-O-beta-D-glucoside
Chinese website: Calycosin-7-O-beta-D-glucoside

[1] Fu S, Gu Y, Jiang J Q, et al. J Ethnopharmacol. 2014,155(1): 692–701.
[2] Jiang Y H, Sun W, Li W, et al. Bmc Compl Altern M, 2015, 15(1):1-11.
[3] Ren M, Wang XD, Du G Q, et al. Mol Med Rep, 2015, 13(1):235–45.
[4] Zhang D M. Chinese Traditional & Herbal Drugs, 2015, 46(10):1498-502.
[5] Song C Y, Feng J F. Chinese J Exp Trad Med Formulae, 2013, 19(11):115-7.